Metabolic hormones and breast cancer risk among Mexican American Women in the Mano a Mano Cohort Study

Jie Shen¹, Daphne Hernandez², Yuanqing Ye³, Xifeng Wu¹, Wong-Ho Chow¹ & Hua Zhao¹

C-peptide, insulin, leptin, and other metabolic hormones are assumed to play roles in breast cancer development; though, results are inconsistent. In this prospective case-control study nested within the Mano a Mano Cohort Study, we assessed the risk of breast cancer with regard to plasma levels of c-peptide, gastric inhibitory polypeptide, insulin, leptin, monocyte chemoattractant protein-1, pancreatic polypeptide, and peptide YY. Among women followed for a median of 8.5 years, 109 breast cancer cases were identified and frequency-matched to 327 controls at a ratio of 1:3. Overall, only c-peptide was observed significantly associated with breast cancer risk. High c-peptide levels (≥ the median level of controls) were significantly associated with increased breast cancer risk (odds ratio [OR] = 1.39, 95% confidence interval [CI]: 1.01, 2.44). In an analysis of participants stratified by age, the significant association between c-peptide levels and breast cancer risk was evident in only women age ≥ 51 years (OR = 1.53, 95% CI: 1.02, 3.27). Among women age < 51 years, high leptin levels were significantly associated with decreased breast cancer risk (OR = 0.49, 95% CI: 0.24, 0.82). Our findings suggest that selected metabolic hormones are associated with breast cancer development in Mexican American women.

Metabolic syndrome and its individual metabolic conditions, including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels, are associated with increased risk of multiple chronic diseases, including cardiovascular disease and cancer¹. Metabolic disorders are related to every step of breast carcinogenesis²–⁷. For example, in the National Institutes of Health–American Association of Retired Persons Diet and Health Study, Dibaba et al. found that women with metabolic syndrome had a 13% higher risk of breast cancer compared with their female counterparts (hazard ratio [HR]: 1.13, 95% confidence interval [CI]: 1.00, 1.27)³. In addition, overwhelming evidence indicates that an excess of body fat is an independent risk factor for breast cancer, particularly among postmenopausal women⁸,⁹. Also, one recent meta-analysis of 28 cohort studies revealed that diabetic patients have a significantly higher risk of breast cancer than nondiabetic patients do (standard rate ratio = 1.13, 95% CI: 1.04, 1.24)¹⁰.

However, the ways in which metabolic syndrome and its individual metabolic conditions link to breast carcinogenesis is still largely undecided. The relationship may be partially mediated by certain metabolic hormones secreted by endocrine system organs, adipocytes, and/or the gastrointestinal tract in response to metabolic stimuli, as some of these hormones are suspected to play roles in breast cancer development. In the current study, we focused on 7 markers: pancreas-derived c-peptide, insulin, and pancreatic polypeptide (PP); gut-derived gastric inhibitory polypeptide (GIP) and peptide YY (PYY); and adipocyte-derived leptin and monocyte chemoattractant protein-1 (MCP-1). Experimental evidence suggests that insulin can promote breast cell growth in vitro and in vivo¹¹,¹². In addition, insulin deters sex hormone binding globulin production¹³, thereby increasing free estradiol and testosterone. C-peptide is a marker of pancreatic insulin secretion¹⁴. Leptin promotes breast cancer cell growth by hindering pro-apoptosis signaling pathways and by preferring sensitivity to estrogens¹⁵. PYY and PP, members of the neuropeptide Y family of peptide hormones, are neurotransmitters; both have roles in appetite regulation and obesity¹⁶,¹⁷. In breast tumors, neuropeptide Y can induce tumor cell growth in a dose-dependent

¹Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
²Department of Health and Human Performance, University of Houston, Texas, USA. Correspondence and requests for materials should be addressed to H.Z. (email: hzhao2@mdanderson.org).
manner\(^{18}\). GIP is an incretin hormone that is involved in regulating circulating glucose and insulin secretion\(^{19}\). Its relationship with breast cancer is unclear, but the GIP receptor has been identified as a therapeutic target in patients with neuroendocrine tumors\(^{20}\). MCP-1, a key pro-inflammatory chemokine that regulates monocyte activity, is involved in various diseases, including cancer\(^{21}\). Recently, MCP-1 was found to be highly expressed in triple-negative breast cancers and consequently involved in tumor invasion and metastasis\(^{22}\).

Investigation of metabolic hormones and their relationships with breast cancer are particularly relevant to Mexican American women, who are experiencing an epidemic of metabolic disorders\(^{23}\). More Mexican American men have elevated fasting glucose levels than non-Hispanic white men do, and more Mexican American women have high waist circumference, reduced high-density lipoprotein cholesterol, and elevated fasting glucose than their non-Hispanic white counterparts do\(^{24}\). To the best of our knowledge, no prospective study has assessed the extent to which metabolic hormone levels are associated with breast cancer risk in Mexican American women. Therefore, in the present study, we measured pre-diagnostic levels of 7 metabolic hormones in plasma samples from 109 breast cancer patients and 327 healthy controls identified from the Mano a Mano Cohort Study and investigated their relationships with breast cancer risk.

Methods

Study population. The study participants were drawn from the ongoing Mano a Mano Cohort Study, a large population-based prospective cohort study of Mexican American households that was initiated in 2001 by the Department of Epidemiology at The University of Texas MD Anderson Cancer Center. Eligible participants in the Mano a Mano Cohort Study had to self-identify as Mexican or Mexican American. Detailed descriptions of the recruitment strategy and data collection procedures have been described previously\(^{24}\). In brief, participants of the Mano a Mano Cohort Study were recruited through community centers, local health clinics, and house-by-house canvassing in predominantly Mexican American neighborhoods in Houston, Texas, and through networking with currently enrolled participants. Eighty-eight percent of the identified eligible households agreed to participate in the study, and written informed consent was obtained from each participant. Trained bilingual research interviewers conducted structured, face-to-face interviews using each participant’s preferred language (either Spanish or English). A standardized and validated questionnaire, which captured information on basic sociodemographic characteristics, residential history, lifestyle behaviors, physical activity, medical history, family history of chronic disease, acculturation, and occupational exposure, was used in the interview. Participants were followed with annual telephone calls to obtain updated information regarding body weight, selected exposures, and diagnosis of selected chronic diseases, including cancer, type 2 diabetes, and hypertension. The cancer cases were further confirmed with the Texas Cancer Registry.

The women were followed until December 1, 2017 (median, 8.2 years). A total of 126 new breast cancers were identified. Among them, 109 were validated through the Texas Cancer Registry and had blood samples that were collected at baseline. For each case, 3 matched controls were selected using an incidence density sampling protocol from appropriate risk sets consisting of cohort members who were alive and free of cancer at the time of diagnosis of the index case. Matching criteria were age at recruitment (±2 years), date of biospecimen collection (±1 year), and gender. Thus, the study included 109 cases and 327 controls. The study protocol was approved by MD Anderson’s Institutional Review Board.

Quantification of metabolic hormones in plasma samples by magnetic bead-based immunoassay. Plasma samples were analyzed using Luminex multiplex technology, which assesses multiple analytes in a single microwell plate, with the MILLIPLEX MAP Human Metabolic Hormone Magnetic Bead Panel (Millipore). This panel enabled the simultaneous analysis of the 7 metabolic hormones of interest: c-peptide, GIP, insulin, leptin, MCP-1, PP, and PYY. The MAGPIX System and an xPONENT 4.2 MAGPIX analyzer (Luminex) were used to analyze the samples. All samples were analyzed in triplicate. Negative controls, standards, and positive controls were included in each plate. Blinded duplicates (5%) were randomly inserted with the samples for quality control purposes. Samples from each case and its 3 matched controls were analyzed in the same plate. Any samples yielding results with an intra-assay coefficient of variation >10% were reanalyzed. The data were processed with xPONENT software using 5-parametric curve fitting and converted to pg/mL. The intra-assay variance was 7% for c-peptide, 5% for GIP, 5% for insulin, 4% for leptin, 8% for MCP-1, 4% for PP, and 6% for PYY.

Statistical analysis. We used the statistical software package SAS version 9.4 (SAS, Cary, NC) for all analyses. First, we evaluated whether selected sociodemographic characteristics and lifestyle behaviors differed between breast cancer patients and healthy controls; the Student t test was used for 2-level dichotomous variables, and analysis of variance was used for variables with more than 2 levels. To assess relationships among metabolic hormones, we evaluated the pairwise correlations between all hormones among the controls. Hormones with pairwise correlations >0.5 were considered to be highly correlated and to have possible redundancy. Next, we used the Wilcoxon rank-sum test to evaluate whether the median plasma levels of metabolic hormones differed according to selected sociodemographic characteristics and lifestyle behaviors of the controls. To control for multiple comparisons, we set the false discovery rate at 0.05\(^{25}\). To assess the effect of plasma levels of metabolic hormones on breast cancer risk, we used unconditional multivariate logistic regression to estimate odds ratios (ORs) and 95% CIs. We ran a minimally adjusted model, adjusting for basic demographic variables (e.g. birthplace, language acculturation, age, parity, body mass index (BMI) category, and education level), and a fully-adjusted model, with the following additional healthy behavior related variables (e.g. smoking status, drinking status, sitting time, and physical activity). Metabolic hormone levels were designated “high” or “low” using the controls’ median levels of the hormones as cutoffs and were assessed as categorical variables. Finally, in an analysis in which participants were stratified by age group, we used similar multivariate logistic regression analysis to assess relationships between metabolic hormones and breast cancer risk.
ethics approval. All procedures in this study were approved by MD Anderson’s Institutional Review Board and performed in accordance with the Declaration of Helsinki.

informed consent. Written informed consent was obtained from all participants.

results
The basic sociodemographic characteristics and lifestyle behaviors of the 109 breast cancer cases and 327 healthy controls are summarized in Table 1. In general, the cases and controls were well-matched. Cases and controls did not differ significantly in terms of age group, parity, education level, birthplace, language acculturation, BMI category, smoking status, alcohol drinking, physical activity, or sitting time.

We investigated the pairwise correlations among the 7 plasma metabolic hormones in the controls and found several significant correlations (Table 2). C-peptide, GIP, insulin, and MCP-1 were significantly correlated with all other markers (P < 0.05). In particular, both c-peptide and GIP were significantly correlated with the other 6 markers (P < 0.001). C-peptide and GIP were most strongly correlated (r = 0.494, P < 0.001). However, no hormones had pairwise correlations >0.5, indicating that none of the hormones were highly correlated or had possible redundancy. In addition, no significant correlation was observed between leptin and PP or between leptin and PYY. After adjustment for multiple comparisons, the significant associations remained (P < 0.05), except for those between MCP-1 and insulin and between MCP-1 and PP.

Table 1. Distribution of characteristics among participants by case control status.
molecular mechanism. C-peptide may 1) potentiate the insulin receptor and/or 2) increase the concentration of.

mia is involved in in breast cancer development. Two hypotheses have been proposed to explore the underlying.
c-peptide with elevated risk of postmenopausal breast cancer is consistent with the notion that hyperinsuline-

age

Y Y.  1P

inhibitory polypeptide; MCP-1, monocyte chemoattractant protein-1; PP, pancreatic polypeptide; PYY, peptide

Table 2. Pairwise correlations between plasma hormone biomarkers among controls. GIP, gut-derived gastric

Discussion

We assessed relationships between the plasma levels of 7 metabolic hormones and sociodemographic char-

cters and lifestyle behaviors among controls (Table 3). As expected, levels of those 7 metabolic hormones

increased significantly with increasing BMI category (P < 0.05). After adjustment for multiple comparisons, c-

peptide, GIP, insulin, leptin, and MCP-1 levels remained significantly associated with BMI category. Plasma

levels of c-peptide, GIP, insulin, MCP-1, and PYY increased significantly with increasing number of sitting hours

day (P < 0.05); even after adjustment for multiple comparisons, c-peptide and insulin levels remained sig-

significantly associated with number of sitting hours. In addition, plasma levels of c-peptide, GIP, and leptin were

higher in women born in the United States than in women born in Mexico, and plasma levels of c-peptide, GIP,

leptin, and MCP-1 were significantly higher in women with low levels of physical activity than in women with

medium or high levels of physical activity; however, these significant associations disappeared after adjustment

for multiple comparisons.

We evaluated the associations between plasma levels of metabolic hormones and breast cancer risk (Table 4).

For each metabolic hormone, we stratified the study participants into 2 groups based on the median plasma

levels of the hormone. We included birth place, language acculturation, age, parity, BMI category, and education

level in Model 1, and birth place, language acculturation, age, parity, BMI category, education level, smoking

status, drinking status, sitting time, and physical activity in Model 2. C-peptide was the only metabolic hormone

significantly associated with breast cancer risk. Compared with women with low c-peptide levels (<5164.5 pg/

ML), women with high c-peptide levels (≥5164.5 pg/mL) had a 1.42-fold higher risk of breast cancer in model 1

(OR = 1.42, 95% CI: 1.02, 2.37) and a 1.39-fold higher risk in model 2 (OR = 1.39, 95% CI: 1.01, 2.44).

When study participants were further stratified using the median age of the controls as a cutoff, higher

c-peptide levels were significantly associated with breast cancer risk in only women age ≥51 years after adjust-

ment for birthplace, language acculturation, parity, BMI category, and education level (OR = 1.53, 95% CI: 1.02,

3.27) (Table 5). Interestingly, among women age <51 years, leptin levels were inversely associated with breast

cancer risk (OR = 0.49, 95% CI: 0.24, 0.82). In addition, we analyzed whether the risk associations differed by

obesity status (Table 5). Unfortunately, no significant association was observed between metabolic hormones and

breast cancer risk in either non-obese or obese group.

Discussion

To our knowledge, the current study was the first to prospectively assess associations between circulating meta-

bolic hormone levels and breast cancer risk in Mexican American women. We found that higher c-peptide levels

were significantly associated with an increased risk of breast cancer and that this risk was more evident among

older women than among younger women. In addition, among younger women, higher leptin levels were significa-

antly associated with a decreased risk of breast cancer.

Several previous studies have investigated the association between pre-diagnostic c-peptide levels and breast

cancer risk26–29. These studies consistently showed a significant relationship between c-peptide levels and breast

cancer risk in older or postmenopausal women27,28 but not younger or premenopausal women26. For example, in

the European Prospective Investigation into Cancer and Nutrition study, higher serum c-peptide levels were asso-

ciated with higher breast cancer risk among women age >60 years, but not among their younger counterparts27.

In the Cancer Prevention Study II Nutrition Cohort, a significant association between higher levels of c-peptide

and breast cancer risk was observed among postmenopausal women29. In agreement with those reports, in the

current study, higher plasma levels of c-peptide were significantly associated with breast cancer risk in women

age ≥51 years (OR = 1.53, 95% CI: 1.02, 3.27) but not women age <51 years. In addition, when younger and older

women were combined together, the association remained significant. Although the observed age difference in risk

association is consistent the literature reports, we cannot exclude the likelihood of probable biases/measurement

error that can influence the observation. Our study used BMI to identify obesity. However, a recent study has

shown that BMI is a suboptimal marker for adiposity in the elderly30. Also, there may exist detection bias since

tumor may be diagnosed later among obese women.

C-peptide, which is released into the blood as a byproduct of insulin, is considered to be a marker of insu-

lin production and hyperinsulinemia31. Hyperinsulinemia with insulin resistance, which causes increased levels

of insulin in circulation, has been linked to breast cancer32–34. Thus, the association of higher plasma levels of

c-peptide with elevated risk of postmenopausal breast cancer is consistent with the notion that hyperinsuline-

mia is involved in in breast cancer development. Two hypotheses have been proposed to explore the underlying

molecular mechanism. C-peptide may 1) potentiate the insulin receptor and/or 2) increase the concentration of

| C-peptide | GIP | Insulin | Leptin | MCP-1 | PP | PYY |
|-----------|-----|---------|--------|-------|----|-----|
| c-peptide | 0.494 1,4 | 0.431 1,4 | 0.357 1,4 | 0.128 1,4 | 0.265 1,4 | 0.183 1,4 |
| GIP       | 0.454 1,4 | 0.131 1,4 | 0.185 1,4 | 0.373 1,4 | 0.332 1,4 |
| Insulin   | 0.368 1,4 | 0.058 1 | 0.277 1,4 | 0.293 1,4 |
| Leptin    | 0.139 1,4 | 0.013 1 | 0.053 1 |
| MCP-1     | 0.088 1,4 | 0.176 1 | 0.176 1 |
| PP        | 0.272 1,4 | 0.272 1,4 |
bioavailable sex hormones, and thereby influence the action of insulin on breast cancer cell growth directly and/or indirectly\(^3\). Additionally, stimulation of the mitogen-activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI-3K) pathways has been proposed to be involved in the action of insulin and its receptor on promoting cell growth\(^17,40\).

| Variable                  | Median c-peptide level, pg/mL | Median GIP level, pg/mL | Median insulin level, pg/mL | Median leptin level, pg/mL | Median MCP-1 level, pg/mL | Median PP level, pg/mL | Median PYY level, pg/mL |
|---------------------------|-------------------------------|-------------------------|-----------------------------|----------------------------|--------------------------|------------------------|-------------------------|
| Overall                   | 5,164.5 (120, 9,548)          | 2,019.5 (17, 8,877)     | 3,352 (192, 2,862)          | 3,096 (192, 2,862)         | 1,976 (24, 7,560)        | 446 (16, 684)          | 230 (155, 1,340)        |
| Age at enrollment         |                               |                         |                             |                            |                          |                        |                         |
| <51 years                 | 4,672                         | 1,990                   | 365                          | 3,352                      | 1,870                    | 431                    | 195                     |
| ≥51 years                 | 5,380                         | 2,289                   | 429                          | 3,896                      | 2,064                    | 462                    | 296                     |
| P value                   | 0.368                         | 0.763                   | 0.378                        | 0.042                      | 0.734                    | 0.523                  | 0.631                   |
| Parity                    |                               |                         |                             |                            |                          |                        |                         |
| Nulliparous               | 4,768                         | 1,973                   | 406                          | 3,529                      | 1,762                    | 426                    | 193                     |
| 1 or 2 children           | 4,980                         | 2,048                   | 372                          | 3,796                      | 1,965                    | 470                    | 240                     |
| >2 children               | 5,432                         | 2,399                   | 416                          | 3,602                      | 2,037                    | 431                    | 226                     |
| P for trend               | 0.272                         | 0.642                   | 0.792                        | 0.826                      | 0.243                    | 0.782                  | 0.843                   |
| Education level           |                               |                         |                             |                            |                          |                        |                         |
| <High school              | 4,971                         | 2,065                   | 411                          | 3,580                      | 1,821                    | 465                    | 205                     |
| High school               | 5,306                         | 2,090                   | 369                          | 3,629                      | 1,879                    | 429                    | 224                     |
| >High school              | 5,025                         | 2,273                   | 392                          | 3,781                      | 2,165                    | 449                    | 239                     |
| P for trend               | 0.872                         | 0.924                   | 0.871                        | 0.762                      | 0.303                    | 0.606                  | 0.682                   |
| Place of birth            |                               |                         |                             |                            |                          |                        |                         |
| Mexico                    | 4,670                         | 1,856                   | 423                          | 3,429                      | 1,772                    | 429                    | 201                     |
| United States             | 5,608                         | 2,437                   | 372                          | 3,906                      | 2,026                    | 458                    | 267                     |
| P value                   | 0.023                         | 0.035                   | 0.392                        | 0.043                      | 0.085                    | 0.682                  | 0.267                   |
| Language acculturation    |                               |                         |                             |                            |                          |                        |                         |
| Low                       | 4,827                         | 2,058                   | 365                          | 3,629                      | 1,987                    | 440                    | 224                     |
| High                      | 5,249                         | 2,199                   | 479                          | 3,702                      | 1,923                    | 466                    | 262                     |
| P value                   | 0.481                         | 0.874                   | 0.562                        | 0.924                      | 0.961                    | 0.796                  | 0.740                   |
| BMI category              |                               |                         |                             |                            |                          |                        |                         |
| Underweight/normal        | 4,556                         | 1,754                   | 329                          | 3,258                      | 1,592                    | 423                    | 201                     |
| Overweight                | 5,072                         | 2,075                   | 387                          | 3,541                      | 1,824                    | 431                    | 219                     |
| Obese                     | 5,591                         | 2,396                   | 463                          | 3,806                      | 2,435                    | 469                    | 260                     |
| P for trend               | <0.001\(^1\)                 | <0.001\(^1\)            | <0.001\(^1\)                | <0.001\(^1\)              | <0.001\(^1\)            | <0.001\(^1\)           | 0.026                   |
| Smoking status            |                               |                         |                             |                            |                          |                        |                         |
| Never                     | 4,892                         | 2,082                   | 368                          | 3,402                      | 1,905                    | 440                    | 223                     |
| Former                    | 5,079                         | 2,187                   | 405                          | 3,706                      | 1,843                    | 453                    | 229                     |
| Current                   | 5,248                         | 2,269                   | 389                          | 3,658                      | 2,089                    | 459                    | 242                     |
| P for trend               | 0.871                         | 0.894                   | 0.764                        | 0.862                      | 0.726                    | 0.823                  | 0.876                   |
| Alcohol drinking          |                               |                         |                             |                            |                          |                        |                         |
| Never                     | 4,979                         | 1,996                   | 382                          | 3,529                      | 1,869                    | 409                    | 211                     |
| Former                    | 5,105                         | 2,257                   | 409                          | 3,685                      | 1,825                    | 460                    | 230                     |
| Current                   | 5,007                         | 2,092                   | 416                          | 3,699                      | 2,192                    | 478                    | 248                     |
| P for trend               | 0.912                         | 0.854                   | 0.871                        | 0.936                      | 0.465                    | 0.432                  | 0.487                   |
| Physical activity         |                               |                         |                             |                            |                          |                        |                         |
| Low                       | 5,409                         | 1,898                   | 372                          | 3,426                      | 1,782                    | 413                    | 219                     |
| Medium or high            | 4,678                         | 2,367                   | 416                          | 3,841                      | 2,354                    | 460                    | 247                     |
| P value                   | 0.012                         | 0.021                   | 0.254                        | 0.019                      | 0.011                    | 0.259                  | 0.305                   |
| Sitting hours/day         |                               |                         |                             |                            |                          |                        |                         |
| <2                        | 4,580                         | 1,846                   | 350                          | 3,453                      | 1,832                    | 413                    | 209                     |
| 2–4                       | 4,792                         | 1,996                   | 369                          | 3,826                      | 1,945                    | 449                    | 226                     |
| 4–6                       | 5,081                         | 2,357                   | 392                          | 3,529                      | 2,306                    | 438                    | 254                     |
| >6                        | 5,434                         | 2,197                   | 413                          | 3,624                      | 2,019                    | 452                    | 243                     |
| P for trend               | P < 0.001\(^1\)              | 0.031                   | <0.001\(^1\)                | 0.258                      | 0.027                    | 0.165                  | 0.041                   |

Table 3. Metabolic hormone levels among controls. GIP, gut-derived gastric inhibitory polypeptide; MCP-1, monocyte chemoattractant protein-1; PP, pancreatic polypeptide; PYY, peptide YY; BMI, body mass index. 

\(^1\)Statistically significant after the adjustment of multiple comparison.
In the present study, plasma c-peptide levels were significantly positively associated with BMI and BMI category. This finding is in line with the notion that obesity causes insulin resistance and hyperinsulinemia. This observation might also help explain the observed age difference in the association between c-peptide and breast cancer risk, as BMI is a protective factor for breast cancer in premenopausal women but a risk factor for breast cancer in postmenopausal women. Nevertheless, the observed risk continued fairly unchanged by adjustments for BMI, signifying that the influence of insulin on breast cancer risk was not related to excess weight.

In our study, the relationship between leptin and breast cancer risk differed depending on age; increased plasma leptin levels were significantly associated with decreased breast cancer risk in younger participants (<51 years old) but not older participants (≥51 years old). This finding is in line with the results of several other cohort studies. For example, in a prospective case-control study nested within the Nurses’ Health Study II cohort, after adjusting for BMI at age 18 years, weight change from age 18 years to blood draw, and other breast cancer risk factors, plasma leptin was a protective factor for breast cancer. Leptin is thought to be a link between obesity and obesity-related complications including metabolic syndrome, type 2 diabetes, and cancer. In breast epithelial cells, leptin can stimulate cell proliferation in obese women by accelerating the change of aromatizable androgens to estradiol. However, among postmenopausal women, their levels of circulating estrogens decline and at high levels may reduce follicular estradiol secretion. Such reduction is particularly relevant to premenopausal or younger women since it can help explain why high leptin may lower breast cancer risk among them.

In the present study, GIP, insulin, leptin, and MCP-1, in addition to c-peptide, were significantly associated with BMI, even after adjustment for multiple comparisons. This finding is consistent with these hormones’ roles in metabolic syndrome and its individual metabolic conditions. We also found that levels of c-peptide and insulin were significantly increased with the time spent sitting per day after multiple comparison adjustment. This is consistent with the observation that being less physically active is a risk factor for insulin resistance.

Our study had several potential limitations. For example, we measured metabolic markers at only one time point, which prevented us from evaluating the value changes over time. Data on menopausal status at the time of diagnosis were lacking. Hence, we chose to use age at diagnosis as an estimation of menopausal status at the time of diagnosis when stratifying participants. In addition, the blood samples used in this study were collected from patients who had not been fasting. Fasting plasma metabolic markers may be better biomarkers than non-fasting ones. Finally, we don’t have data on estrogen status so we cannot assess whether the relationships between plasma metabolic hormones and breast cancer risk differ by tumor subtype. A few studies have suggested that the relationship between obesity and breast cancer risk differs between estrogen receptor positive (ER+) and ER− breast tumors in postmenopausal women. Given the strong correlations between those metabolic hormones and obesity, it is likely that the observed associations between plasma metabolic hormones and breast cancer risk

| Hormone | Cases | Controls | Model 1 | Model 2 |
|---------|-------|----------|---------|---------|
| C-peptide |       |          |         |         |
| <5164.5 pg/mL | 44 (40.37) | 163 (49.85) | 1.00 | 1.00 |
| ≥5164.5 pg/mL | 65 (59.63) | 164 (50.15) | 1.42 (1.02, 2.37) | 1.39 (1.01, 2.44) |
| GIP |       |          |         |         |
| <2191.5 pg/mL | 52 (47.71) | 164 (50.15) | 1.00 | 1.00 |
| ≥2191.5 pg/mL | 57 (52.29) | 163 (49.85) | 1.09 (0.67, 1.79) | 1.06 (0.63, 1.84) |
| Insulin |       |          |         |         |
| <390 pg/mL | 50 (45.87) | 162 (49.54) | 1.00 | 1.00 |
| ≥390 pg/mL | 59 (54.13) | 165 (50.46) | 1.12 (0.70, 1.87) | 1.08 (0.64, 1.96) |
| Leptin |       |          |         |         |
| <3675.5 pg/mL | 60 (55.05) | 164 (50.15) | 1.00 | 1.00 |
| ≥3675.5 pg/mL | 49 (44.95) | 163 (49.85) | 0.84 (0.50, 1.31) | 0.85 (0.48, 1.35) |
| MCP-1 |       |          |         |         |
| <1976 pg/mL | 53 (48.62) | 162 (49.54) | 1.00 | 1.00 |
| ≥1976 pg/mL | 56 (51.38) | 165 (50.46) | 1.04 (0.53, 1.67) | 1.01 (0.48, 1.75) |
| PP |       |          |         |         |
| <446 pg/mL | 54 (49.54) | 163 (49.85) | 1.00 | 1.00 |
| ≥446 pg/mL | 55 (50.46) | 164 (50.15) | 1.02 (0.45, 1.74) | 1.01 (0.43, 1.77) |
| PYY |       |          |         |         |
| <230 pg/mL | 52 (47.71) | 164 (50.15) | 1.00 | 1.00 |
| ≥230 pg/mL | 57 (52.29) | 163 (49.85) | 1.07 (0.64, 1.80) | 1.05 (0.62, 1.86) |

Table 4. Risk for developing breast cancer in relation to median levels of plasma hormone biomarkers. GIP, gut-derived gastric inhibitory polypeptide; MCP-1, monocyte chemoattractant protein-1; PP, pancreatic polypeptide; PYY, peptide YY. 1Adjusted for birthplace, language acculturation, age, parity, body mass index category, and education level. 2Adjusted for birthplace, language acculturation, age, parity, body mass index category, education level, smoking status, drinking status, sitting time, and physical activity.
are more evident among for ER+ than ER- breast tumors. However, in an analysis from Nurse Health Study, the association between plasma c-peptide and breast cancer was stronger among ER- than ER+ breast tumors48. Clearly, more studies at here filed are needed.

Conclusions
Despite these potential limitations, our results provide the first evidence that higher c-peptide levels are significantly associated with increased breast cancer risk among older Mexican American women and that higher leptin levels are significantly associated with decreased risk of breast cancer among younger Mexican American women. Large prospective studies to validate our results are warranted.

Table 5. Risk for developing breast cancer in relation to median levels of plasma hormone biomarkers by age category. GIP, gut-derived gastric inhibitory polypeptide; MCP-1, monocyte chemoattractant protein-1; PP, pancreatic polypeptide; PYY, peptide YY. 1Adjusted for birthplace, language acculturation, parity, body mass index category, and education level as appropriate.

| Hormone | Age < 51 years | Age ≥ 51 years | non-obese | Obese |
|---------|----------------|----------------|-----------|-------|
| C-peptide |                |                |           |       |
| Low     | 1.00           | 1.00           | 1.00      | 1.00  |
| High    | 1.36 (0.87, 3.56) | 1.53 (1.02, 3.27) | 1.37 (0.90, 3.78) | 1.46 (0.98, 3.69) |
| GIP     |                |                |           |       |
| Low     | 1.00           | 1.00           | 1.00      | 1.00  |
| High    | 1.03 (0.59, 3.98) | 1.08 (0.52, 4.01) | 1.05 (0.60, 3.75) | 1.06 (0.50, 3.86) |
| Insulin |                |                |           |       |
| Low     | 1.00           | 1.00           | 1.00      | 1.00  |
| High    | 1.06 (0.63, 3.83) | 1.05 (0.59, 4.10) | 1.03 (0.60, 3.79) | 1.04 (0.58, 4.02) |
| Leptin  |                |                |           |       |
| Low     | 1.00           | 1.00           | 1.00      | 1.00  |
| High    | 0.49 (0.24, 0.82) | 1.39 (0.92, 3.76) | 0.75 (0.43, 1.92) | 1.28 (0.90, 3.81) |
| MCP-1   |                |                |           |       |
| Low     | 1.00           | 1.00           | 1.00      | 1.00  |
| High    | 0.89 (0.43, 3.59) | 1.23 (0.57, 4.05) | 1.04 (0.41, 4.06) | 0.99 (0.40, 4.12) |
| PP      |                |                |           |       |
| Low     | 1.00           | 1.00           | 1.00      | 1.00  |
| High    | 0.93 (0.39, 3.77) | 1.04 (0.47, 3.97) | 0.98 (0.43, 3.86) | 1.02 (0.49, 4.01) |
| PYY     |                |                |           |       |
| Low     | 1.00           | 1.00           | 1.00      | 1.00  |
| High    | 0.99 (0.40, 3.85) | 1.07 (0.51, 4.08) | 0.98 (0.39, 4.01) | 1.02 (0.43, 3.99) |

References
1. Expert Panel on Detection E, Treatment of High Blood Cholesterol In A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001).
2. Dibaba, D. T., Ogunsina, K., Braithwaite, D. & Akinyemiju, T. Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype. Breast Cancer Res Treat, https://doi.org/10.1007/s10549-018-5056-8 (2018).
3. Dibaba, D. T., Braithwaite, D. & Akinyemiju, T. Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin? J Diabetes Res, 14 (2016).
4. Agnoli, C. et al. Metabolic syndrome and breast cancer risk: a case-cohort study nested in a multicentre italian cohort. PLoS One 10(6), e0128891, https://doi.org/10.1371/journal.pone.0128891 (2015).
5. Bhandari, R., Kelley, G. A., Hartley, T. A. & Rockett, I. R. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int J Breast Cancer 2014, 189384, https://doi.org/10.1155/2014/189384 (2014).
6. Ibarra-Drendall, C., Dietze, E. C. & Seewaldt, V. L. Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin? Curr Breast Cancer Rep 3(3), 142–150, https://doi.org/10.1007/s12609-011-0050-8 (2011).
7. Porto, L. A., Lora, K. J., Soares, J. C. & Costa, L. O. Metabolic syndrome is an independent risk factor for breast cancer. Arch Gynecol Obstet 284(5), 1271–1276, https://doi.org/10.1007/s00404-011-1837-6 (2011).
8. Wiseman, M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 67(3), 253–256, https://doi.org/10.1017/S0007209X0800712X (2008).
9. Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, J. J., Friedman, E. R. & Slingerland, J. M. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin 67(5), 378–397, https://doi.org/10.3322/caac.21405 (2017).
10. MARIA BOTA PAaPB. The Risk of Breast Cancer in Women with Diabetes. Diabetes 67(Supplement 1) (2018).
11. Milazzo, G. et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52(14), 3924–3930 (1992).
12. Papa, V., Milazzo, G., Goldfine, I. D., Waldman, F. M. & Vigneri, R. Sporadic amplification of the insulin receptor gene in human breast cancer. J Endocrinol Invest 20(9), 531–536, https://doi.org/10.1007/BF03348015 (1997).
13. Singh, A. et al. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. J Endocrinol 124(2), R1–3 (1990).
14. Bonser, A. M. & Garcia-Webb, P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci 19(4), 297–352, https://doi.org/10.1097/0108368409165766 (1984).
15. Jarde, T., Perrier, S., Vasson, M. P. & Caldeffe-Chezet, F. Molecular mechanisms of leptin and adiponectin in breast cancer. *Eur J Cancer* **47**(1), 33–43, https://doi.org/10.1016/j.ejca.2010.09.005 (2011).

16. Karra, E., Chandarana, K. & Batterham, R. L. The role of peptide YY in appetite regulation and obesity. *J Physiol* **587**(1), 19–25, https://doi.org/10.1113/jphysiol.2008.164269 (2009).

17. Koska, J., DellParigi, A., de Courten, B., Weyer, C. & Tatarni, P. A. Pancreatic polypeptide is involved in the regulation of body weight in plasma Indian male subjects. *Diabetes* **58**(12), 3091–3096, https://doi.org/10.2327/diabetes.58.12.3091 (2004).

18. Reubi, J. C., Guerrer, M., Waser, B. & Scher, J. C. Y(1)-mediated effect of neurotrophin Y in cancer: breast carcinomas as targets. *Cancer Res* **61**(11), 4636–4641 (2001).

19. Meier, J. I. et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euaglycemia. *Diabetologia* **46**(6), 798–801, https://doi.org/10.1007/s00125-003-1103-y (2003).

20. Sherman, S. K. et al. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. *Surgery* **154**(6), 1206–1213, https://doi.org/10.1016/j.surg.2013.04.025 (2013).

21. Deshmahne, S. L., Kremlev, S., Amini, S. & Sawaya, R. E. Monocyte Chemooactant Protein-1 (MCP-1): An Overview. *J Interf Cytok Res* **29**(6), 313–326, https://doi.org/10.1089/jir.2008.0077 (2009).

22. Dutta, P., Sarkisyan, M., Paico, K., Wu, Y. Y. & Vagadama, J. V. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. *Breast Cancer Res Tr* **17**(0), 477–486, https://doi.org/10.1007/s11136-014-0670-8 (2018).

23. Moore, J. X., Chaudhary, N. & Akinyemiju, T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. *Prev Chronic Dis* **14**, E24, https://doi.org/10.5888/pcd14.160287 (2017).

24. Chow, W. H. et al. Cohort Profile: The Mexican American Mano a Mano Cohort. *Int J Epidemiol* **46**(2), e3, https://doi.org/10.1093/ije/dyv016 (2017).

25. Chong, E. Y. et al. Local false discovery rate estimation using feature reliability in LC/MS metabolomics data. *Sci Rep* **5**, 17221, https://doi.org/10.1038/srep17221 (2015).

26. Eliasen, A. H., Tworoger, S. S., Mantzoros, C. S., Pollak, M. N. & Hankinson, S. E. Circulating insulin and C-peptide levels and risk of breast cancer among predominately premenopausal women. *Cancer Epidem Biomar* **16**(1), 161–164, https://doi.org/10.1158/1055-9965.Epi-06-0693 (2007).

27. Verheus, M. et al. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* **119**(3), 659–667, https://doi.org/10.1002/ijc.21861 (2006).

28. Autier, P. et al. Serum insulin and C-peptide concentration and breast cancer: a meta-analysis. *Cancer Cause Control* **24**(5), 873–883, https://doi.org/10.1007/s10552-013-0164-6 (2013).

29. Gaudet, M. M. et al. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. *Int J Mol Epidemiol Genet* **4**(3), 156–166 (2013).

30. Batsis, J. A. et al. Diagnostic accuracy of body mass index to identify obesity in older adults: NHANES 1999–2004. *Int J Obes (Lond)* **40**(5), 761–767, https://doi.org/10.1038/ijo.2015.243 (2016).

31. Relimpio, F. et al. Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. *Diabetes Res Clin Pract* **36**(3), 173–180 (1997).

32. Bruning, P. F. et al. Insulin resistance and breast-cancer risk, *Int J Cancer* **52**(4), 511–516 (1992).

33. Muts, P. et al. Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk; a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). *Cancer Causes Control* **11**(8), 721–730 (2000).

34. Sinagra, D. et al. Metabolic syndrome and breast cancer risk, *Eur Rev Med Pharmacol Sci* **62**(3–4), 55–59 (2002).

35. Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. *Nat Rev Cancer* **8**(12), 915–928, https://doi.org/10.1038/nrc2536 (2008).

36. Pollak, M. N. Insulin-like growth factors and neoplasia. *Novartis Found Symp* **262**, 84–98, discussion 98–107, 265–108 (2004).

37. Harris, H. R., Tworoger, S. S., Hankinson, S. E., Rosner, B. A. & Michels, K. B. Plasma leptin levels and risk of breast cancer in young Indian female subjects. *Diabetes* **53**(12), 3091–3096, https://doi.org/10.2327/diabetes.53.12.3091 (2004).

38. Reubi, J. C., Guerrer, M., Waser, B. & Scher, J. C. Y(1)-mediated effect of neurotrophin Y in cancer: breast carcinomas as targets. *Cancer Res* **61**(11), 4636–4641 (2001).

**Acknowledgements**

We thank the field staff for their ongoing work with participant recruitment and follow-up. Most importantly, we thank our study participants and their parents for their cooperation and participation, without which this research would not be possible. We acknowledge MD Anderson’s Department of Scientific Publications for editing the manuscript. The Mano a Mano Cohort Study receives funds collected pursuant to the Comprehensive Tobacco Settlement of 1998 and appropriated by the 76th legislature to The University of Texas MD Anderson Cancer Center as well as funds from the Caroline W. Law Fund for Cancer Prevention and the Duncan Family Institute for Risk Assessment and Cancer Prevention. The study partially funded by P20CA221696 (D.H. and H.Z.).
Author Contributions
J.S., D.H., X.W., W.C. and H.Z. participated in study design. J.S. performed the molecular analysis. Y.Y. performed the data analysis. J.S. and H.Z. drafted the manuscript.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019